Everolimus or sunitinib as first-line treatment of metastatic papillary renal cell carcinoma: A retrospective study of the GETUG group (Groupe d'Etude des Tumeurs Uro-Genitales) - Résistances Thérapeutiques du Cancer de la Prostate Accéder directement au contenu
Article Dans Une Revue European Journal of Cancer Année : 2021

Everolimus or sunitinib as first-line treatment of metastatic papillary renal cell carcinoma: A retrospective study of the GETUG group (Groupe d'Etude des Tumeurs Uro-Genitales)

1 CHRU Tours - Centre Hospitalier Régional Universitaire de Tours
2 Service d'Anatomopathologie [Tours]
3 UNICANCER/ICO - Institut de Cancérologie de l'Ouest [Angers/Nantes]
4 IUCT Oncopole - UMR 1037 - Institut Universitaire du Cancer de Toulouse - Oncopole
5 Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Ponchaillou]
6 Département d'oncologie médicale [Rennes]
7 CRLCC - CRLCC Eugène Marquis
8 HEGP - Hôpital Européen Georges Pompidou [APHP]
9 Hôpital Saint-André
10 CRCM - Centre de Recherche en Cancérologie de Marseille
11 IPC - Institut Paoli-Calmettes
12 Hôpital Cochin [AP-HP]
13 PRETRRAM (URP_4466) - Prévention et traitement de la perte protéique musculaire en situation de résistance à l'anabolisme
14 UNICANCER/CRLC - Centre Régional de Lutte contre le Cancer François Baclesse [Caen]
15 CHU de Poitiers [La Milétrie] - Centre hospitalier universitaire de Poitiers = Poitiers University Hospital
16 ICHUSE - Institut de Cancérologie et d'Hématologie Universitaire de Saint-Étienne [CHU Saint-Etienne]
17 UNICANCER/CRLCC-CGFL - Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon]
18 UNICANCER/Lille - Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille]
19 CHRU Lille - Centre Hospitalier Régional Universitaire [CHU Lille]
20 EA 2694 - Santé Publique : épidémiologie et qualité des soins
21 Département cancer environnement (Centre Léon Bérard - Lyon)
22 CHU Strasbourg - Centre Hospitalier Universitaire [Strasbourg]
23 CHU Henri Mondor [Créteil]
24 TRePCa - Résistances Thérapeutiques du Cancer de la Prostate
Félix Lefort
  • Fonction : Auteur
Bernard Escudier
  • Fonction : Auteur
Claude Linassier
Laurence Albiges
  • Fonction : Auteur

Résumé

Background: Two phase II trials (NCT00688753 and NCT00541008) reported efficacy data of sunitinib and everolimus in first-line treatment of metastatic papillary renal cell carcinoma (mpRCC). Although most patients receive sunitinib or a mammalian target of rapamycin (mTOR) inhibitor in first-and second-line treatment, the optimal strategy remained unknown. Material and methods: In 23 centres of the Groupe d'Etude des Tumeurs Urogenitales group, after centralised pathological review, we analysed retrospectively progression-free survival (PFS) of patients with mpRCC treated in first-line treatment (PFS-1) with sunitinib or everolimus (primary end-point), PFS in second-line treatment (PFS-2), overall survival (OS), objective response rate, disease control rate (DCR), overall sequence and prognostic factors for OS (secondary end-points). Results: One hundred thirty-eight patients (119 men and 19 women), median age 62.5 years, with mpRCC type 1 (n = 24) or non-type 1 (n = 114), received first-line sunitinib (n = 107) or everolimus (n = 31). With a median follow-up of 92 months, we found no significant difference between the treatment groups in terms of PFS-1 (5.5 versus 6.2 months) and DCR (69% versus 83%). Ninety-eight patients received a second-line treatment, 69% with mTOR inhibitors after sunitinib and 100% with tyrosine kinase inhibitors after everolimus, with similar DCR (64% versus 58%), median PFS-2 (3.4 versus 4.8 months) and OS (16.0 versus 20.3 months). No factor was prognostic for PFS-1, whereas leukocytosis, anaemia and the time from diagnosis to first systemic therapy < 1 year were prognostic for OS. We found no prognostic difference between both pRCC subtypes. The International Metastatic Renal Cell Database Consortium risk factors were prognostic for OS. Conclusion: Sunitinib and everolimus had similar efficacy in first-line treatment of patients with mpRCC. 2021 Elsevier Ltd. All rights reserved.
Fichier principal
Vignette du fichier
S0959804921005785.pdf (273.34 Ko) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-04242387 , version 1 (16-10-2023)

Licence

Identifiants

Citer

Mathilde Cancel, Gaelle Fromont, Cyriac Blonz, Christine Chevreau, Nathalie Rioux-Leclercq, et al.. Everolimus or sunitinib as first-line treatment of metastatic papillary renal cell carcinoma: A retrospective study of the GETUG group (Groupe d'Etude des Tumeurs Uro-Genitales). European Journal of Cancer, 2021, 158, pp.1-11. ⟨10.1016/j.ejca.2021.08.046⟩. ⟨hal-04242387⟩
144 Consultations
7 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More